In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 62-68

  Meletiadis, J ^a   Meis, J F G M ^a   Mouton, J W ^a   Rodriquez Tudela, J L ^a   Donnelly, J P ^a   Verweij, P E ^a   Roilides, E ^a   Maglaveras, N ^a   Abrahamsen, T ^a   Gaustad, P ^a   Denning, D W ^a   Petrikkos, G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; LIPOSOME; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG FORMULATION; FUNGUS CULTURE; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM PROLIFICANS;

ANTIFUNGAL AGENTS; HUMANS; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; NYSTATIN; SCEDOSPORIUM;

EID: 0036136089     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.62-68.2002     Document Type: Article

References (38)

1. Preparing to analyse data
2. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): Four fatal cases in leukemic patients
3. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
4. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature
5. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor
6. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole
7. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
8. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
9. Clinical pharmacokinetics of systemic antifungal drugs
10. Fatal disseminated Scedosporium inflatum infection in a neutropenic immunocompromised patient
11. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
12. Clinical, pathologic and epidemiologic features of infection with Scedosporium prolificans: Four cases and review
13. A case of disseminated Scedosporium apiospermum infection after bone marrow transplantation
14. Disseminated infection due to Scedosporium apiospermum in liver transplantation. Differential diagnosis from invasive aspergillosis
15. Scedosporium prolificans, a multiresistant fungus, from a U.K. AIDS patient
16. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
17. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: A case of mistaken identity
18. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications
19. A new species of Scedosporium associated with osteomyelitis in humans
20. Disseminated Scedosporium infiatum infection in a patient with acute myeloblastic leukemia
21. Developments in hyalohyphomycosis and phaeohyphomycosis
22. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
23. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans
24. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans
25. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: Case report
26. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystalin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole
27. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy
28. Successful treatment of Scedosporium apiospermum suppurative arthritis with itraconazole
29. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation
30. Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation
31. Scedosporium inflatum, an emerging pathogen
32. Pulmonary tuberculosis associated with invasive pseudallescheriasis
33. Clinical significance of Pseudallescheria boydii: A review of 10 years' experience
34. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy
35. Scedosporium inflatum: Clinical spectrum of a newly recognized pathogen
36. Clinical features of human infection with Scedosporium inflatum